Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.
Standard
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. / Munshi, Nikhil C; Anderson, Kenneth C; Bergsagel, P Leif; Shaughnessy, John; Palumbo, Antonio; Durie, Brian; Fonseca, Rafael; Stewart, A Keith; Harousseau, Jean-Luc; Dimopoulos, Meletios; Jagannath, Sundar; Hajek, Roman; Sezer, Orhan; Kyle, Robert; Sonneveld, Pieter; Cavo, Michele; Rajkumar, S Vincent; Jesus, San Miguel; Crowley, John; Avet-Loiseau, Hervé.
in: BLOOD, Jahrgang 117, Nr. 18, 18, 2011, S. 4696-4700.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.
AU - Munshi, Nikhil C
AU - Anderson, Kenneth C
AU - Bergsagel, P Leif
AU - Shaughnessy, John
AU - Palumbo, Antonio
AU - Durie, Brian
AU - Fonseca, Rafael
AU - Stewart, A Keith
AU - Harousseau, Jean-Luc
AU - Dimopoulos, Meletios
AU - Jagannath, Sundar
AU - Hajek, Roman
AU - Sezer, Orhan
AU - Kyle, Robert
AU - Sonneveld, Pieter
AU - Cavo, Michele
AU - Rajkumar, S Vincent
AU - Jesus, San Miguel
AU - Crowley, John
AU - Avet-Loiseau, Hervé
PY - 2011
Y1 - 2011
N2 - A panel of members of the 2009 International Myeloma Workshop developed guidelines for risk stratification in multiple myeloma. The purpose of risk stratification is not to decide time of therapy but to prognosticate. There is general consensus that risk stratification is applicable to newly diagnosed patients; however, some genetic abnormalities characteristic of poor outcome at diagnosis may suggest poor outcome if only detected at the time of relapse. Thus, in good-risk patients, it is necessary to evaluate for high-risk features at relapse. Although detection of any cytogenetic abnormality is considered to suggest higher-risk disease, the specific abnormalities considered as poor risk are cytogenetically detected chromosomal 13 or 13q deletion, t(4;14) and del17p, and detection by fluorescence in situ hybridization of t(4;14), t(14;16), and del17p. Detection of 13q deletion by fluorescence in situ hybridization only, in absence of other abnormalities, is not considered a high-risk feature. High serum ?(2)-microglobulin level and International Staging System stages II and III, incorporating high ?(2)-microglobulin and low albumin, are considered to predict higher risk disease. There was a consensus that the high-risk features will change in the future, with introduction of other new agents or possibly new combinations.
AB - A panel of members of the 2009 International Myeloma Workshop developed guidelines for risk stratification in multiple myeloma. The purpose of risk stratification is not to decide time of therapy but to prognosticate. There is general consensus that risk stratification is applicable to newly diagnosed patients; however, some genetic abnormalities characteristic of poor outcome at diagnosis may suggest poor outcome if only detected at the time of relapse. Thus, in good-risk patients, it is necessary to evaluate for high-risk features at relapse. Although detection of any cytogenetic abnormality is considered to suggest higher-risk disease, the specific abnormalities considered as poor risk are cytogenetically detected chromosomal 13 or 13q deletion, t(4;14) and del17p, and detection by fluorescence in situ hybridization of t(4;14), t(14;16), and del17p. Detection of 13q deletion by fluorescence in situ hybridization only, in absence of other abnormalities, is not considered a high-risk feature. High serum ?(2)-microglobulin level and International Staging System stages II and III, incorporating high ?(2)-microglobulin and low albumin, are considered to predict higher risk disease. There was a consensus that the high-risk features will change in the future, with introduction of other new agents or possibly new combinations.
KW - Humans
KW - Risk Factors
KW - Prognosis
KW - Chromosome Aberrations
KW - Recurrence
KW - Neoplasm Staging
KW - Gene Expression Profiling
KW - Multiple Myeloma/genetics/pathology/therapy
KW - Humans
KW - Risk Factors
KW - Prognosis
KW - Chromosome Aberrations
KW - Recurrence
KW - Neoplasm Staging
KW - Gene Expression Profiling
KW - Multiple Myeloma/genetics/pathology/therapy
M3 - SCORING: Journal article
VL - 117
SP - 4696
EP - 4700
JO - BLOOD
JF - BLOOD
SN - 0006-4971
IS - 18
M1 - 18
ER -
